Beam Therapeutics Inc

beamtx.com

Beam Therapeutics Inc (NASDAQ: BEAM) is a clinical-stage genetic medicines company that develops base editing therapies designed to make precise changes to DNA and RNA. The company does not generate product revenue from approved medicines. It funds operations primarily through collaboration agreements, upfront payments, and milestone payments from partners, as disclosed in its 10-K filed 2026-02-24 (accession 0001193125-26-065194). Beam is a pre-commercial biotechnology company operating entirely at the research and clinical development stage. No approved products, segment revenue breakdown, customer counts, or competitor names are identified in the available filing excerpts, and no such details are included here.

Products & Services

Base editing genetic medicines in clinical and preclinical development. No approved products identified in the available filing excerpts.

Revenue Model

Collaboration agreements, upfront payments, and milestone payments from partners. No approved product revenue as of the 10-K filed 2026-02-24.

Peers: AMICUS THERAPEUTICS, INC. Arrowhead Pharmaceuticals Inc Blueprint Medicines Corp ChemoCentryx, Inc. Denali Therapeutics Inc Mirati Therapeutics, Inc. PTC Therapeutics Inc Ultragenyx Pharmaceutical Inc

Source: SEC 10-K, filed 2026-02-24

Dive deeper

Financial Snapshot

Revenue

TTM

$164.0M

Gross Margin

Last 4 Quarters

N/A

Net Income

TTM

-$65.04M

Current Assets

2026 Q1

$1.267B

Current Liabilities

2026 Q1

$74.57M

Current Ratio

2026 Q1

1699.13%

Total Assets

2026 Q1

$1.481B

Total Liabilities

2026 Q1

$316.4M

Book Value

2026 Q1

1.164B

Cash

2026 Q1

$288.3M

P/E

Last 4 Quarters

N/A

Free Cash Flow

TTM

-$383.8M

Stock Price

Market Cap: $3.3621 Billion